NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

I agree Nick119, by having DCVax-L as an approved treatment option for all ndGBM and rGBM patients, including unmethylated MGMT status patients, physicians will be able to combine DCVax-L with other FDA approved options like a PD-1 Inhibitor, such as Pembrolizumab (Keytruda).

I do not believe the FDA and other regulatory authorities will penalize unmethylated patients, by withholding DCVax-L as a treatment option.